Sai Life Sciences Intrinsic Value
Sai Life Sciences (SAILIFE) median intrinsic value is ₹2031.03 from 9 valuation models (range ₹370–₹2466), vs current price ₹1232.90 — +64.7% upside (Trading Below Calculated Value), margin of safety 39.3%. For current market price and key ratios, visit Sai Life Sciences share price screener.
SAILIFE Valuation Methods Summary — DCF, Graham Number & P/E
Sai Life Sciences intrinsic value across 9 models vs current price ₹1232.90 — upside/downside and value range per method. Read SAILIFE dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹433.84 | ₹347.07 - ₹520.61 | -64.8% | EPS: ₹19.72, Sector P/E: 22x |
| Book Value Method | asset | ₹2365.71 | ₹2129.14 - ₹2602.28 | +91.9% | Book Value/Share: ₹1182.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2354.29 | ₹2118.86 - ₹2589.72 | +91.0% | Revenue/Share: ₹1177.14, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2465.80 | ₹2219.22 - ₹2712.38 | +100.0% | EBITDA: ₹768.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2031.03 | ₹1624.82 - ₹2437.24 | +64.7% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹369.87 | ₹332.88 - ₹406.86 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹369.87 | ₹332.88 - ₹406.86 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2465.80 | ₹2219.22 - ₹2712.38 | +100.0% | ROE: 16.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹724.45 | ₹652.01 - ₹796.90 | -41.2% | EPS: ₹19.72, BVPS: ₹1182.86 |
SAILIFE Intrinsic Value vs Market Price — All Valuation Models
Sai Life Sciences fair value range ₹370–₹2466 vs current market price ₹1232.90 across 9 valuation models. Analyse Sai Life Sciences ownership pattern to track promoter, FII and institutional holdings.
SAILIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Sai Life Sciences median intrinsic value ₹2031.03, current price ₹1232.90 — Trading Below Calculated Value by 64.7%, margin of safety 39.3%.
What is the intrinsic value of SAILIFE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sai Life Sciences (SAILIFE) is ₹2031.03 (median value). With the current market price of ₹1232.90, this represents a +64.7% variance from our estimated fair value.
The valuation range spans from ₹369.87 to ₹2465.80, indicating ₹369.87 - ₹2465.80.
Is SAILIFE undervalued or overvalued?
Based on our multi-method analysis, Sai Life Sciences (SAILIFE) appears to be trading below calculated value by approximately 64.7%.
SAILIFE Financial Health — Key Ratios vs Industry Benchmarks
Sai Life Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.57 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SAILIFE Cash Flow Quality — Operating & Free Cash Flow
Sai Life Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹314 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹263 Cr | ₹168 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹219 Cr | ₹170 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹105 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-36 Cr | ₹-166 Cr | Negative Cash Flow | 3/10 |